Abbott price targets cut after Q4 Nutrition segment drops 9% to $1.94B
Barclays lowered its target on Abbott from $169 to $142 with a 27% upside while Bernstein cut its target from $154 to $125 implying 12% potential gains. Abbott’s Q4 revenue rose 3% organically to $11.46 billion but Nutrition sales fell 9% to $1.94 billion, driving 75% of the quarterly miss.
1. Analyst Price Target Revisions
In early February, Barclays reduced its price target on Abbott from $169 to $142, maintaining an Overweight rating, while Bernstein lowered its target from $154 to $125 with an Outperform rating. These adjustments reflect revised forecasts and target multiples based on the company’s own outlook and segment performance.
2. Q4 Financial Performance
Abbott reported fourth-quarter revenue of $11.46 billion, marking 3% organic growth yet missing consensus by 3%. The Nutrition segment declined 9% to $1.94 billion, accounting for 75% of the quarterly sales shortfall and weighing on overall results.
3. Segment Recovery Outlook
Analysts anticipate improvement in the Nutrition and Diagnostics segments during 2026 as deflated forecasts and target multiples reset expectations. Ongoing struggles are expected to abate, positioning Abbott to benefit from segment rebounds later in the year.